According to a new report by Expert Market Research, the Australia Contract Development and Manufacturing Organization (CDMO) Market was valued at USD 2.03 Billion in 2025 and is projected to reach USD 3.99 Billion by 2035, growing at a CAGR of 7.0% during 2026–2035. Expert Market Research highlights that the industry is being shaped by biologics expansion, advanced clinical trial infrastructure, and rising outsourcing demand in pharmaceutical manufacturing.

The report provides detailed insights into evolving outsourcing trends. Expert Market Research emphasizes that Australia’s strong regulatory ecosystem and skilled workforce are attracting global CDMO partnerships.

Expert Market Research identifies several growth drivers including increasing biologics demand, expansion of sterile injectable production, rising investment in local manufacturing facilities, supportive government funding, and growing pharmaceutical R&D outsourcing activities.

Download a Free Sample Report Including TOC

Market outlook remains positive as Australia strengthens its position as a regional CDMO hub. Expert Market Research notes that sustained investments in mRNA, biologics, and advanced therapies will continue to support long-term expansion of the sector.

Market Overview

Australia’s CDMO ecosystem is evolving rapidly, supported by advanced healthcare infrastructure and strong compliance frameworks. Expert Market Research observes that increasing demand for outsourced pharmaceutical production is enhancing Australia’s global competitiveness in high-value biologics and specialty drug manufacturing. The sector continues to benefit from strong collaboration between public institutions and private manufacturers, ensuring steady innovation and capacity expansion.

Market Size & Forecast: Expert Market Research Projections

The Australia CDMO Market was valued at USD 2.03 Billion in 2025 and is expected to grow at a CAGR of 7.0% during 2026–2035, reaching USD 3.99 Billion by 2035.

Macroeconomic & Industry Linkage Analysis

Australia’s macroeconomic environment supports pharmaceutical innovation through strong regulatory oversight and government-backed funding programs. Investments in biotechnology and life sciences infrastructure are improving manufacturing capabilities and enhancing global competitiveness.

Global supply chain diversification trends are also encouraging pharmaceutical companies to outsource production to reliable CDMO partners in Australia, ensuring resilience and efficiency in drug development processes.

Key Growth Drivers

• Biologics Expansion: Increasing demand for advanced biologics and biosimilars is strengthening CDMO adoption.
• Outsourcing Demand: Pharmaceutical companies are increasingly outsourcing manufacturing to reduce costs and improve efficiency.
• Government Support: Funding initiatives are promoting local pharmaceutical manufacturing capacity.
• Technological Advancements: Innovations in drug formulation and manufacturing technologies are enhancing productivity.
• Clinical Research Growth: Rising clinical trials are boosting demand for development and manufacturing services.

Market Trends

One of the key trends in the market is the rising adoption of biologics and personalized medicine, which is significantly increasing demand for specialized CDMO services. Expert Market Research highlights that companies are focusing on advanced manufacturing platforms to support complex drug development pipelines.

Another major trend is the expansion of strategic partnerships between global pharmaceutical companies and local CDMOs in Australia. These collaborations are improving production efficiency and accelerating time-to-market for new therapies.

Market Challenges & Risk Factors

High operational costs and strict regulatory requirements pose challenges for CDMO providers in Australia. Maintaining compliance with evolving global standards requires continuous investment in quality systems and infrastructure.

Additionally, limited large-scale manufacturing capacity compared to global hubs can restrict rapid scalability for certain drug categories, creating competitive pressure.

Market Opportunities & White Space Areas

Significant opportunities exist in biologics manufacturing, mRNA vaccine production, and sterile injectable development. These high-value segments are attracting strong investment from global players.

Emerging opportunities in advanced therapies and personalized medicine also present untapped potential for CDMO expansion in Australia.

Value Chain & Supply Chain Analysis

The CDMO value chain in Australia includes early-stage drug development, clinical trial manufacturing, scale-up production, and commercial manufacturing. Efficient supply chain integration ensures seamless transition between development stages, enhancing productivity and reducing time-to-market.

Market Segmentation Analysis

Breakup By Service Type

• Contract Manufacturing Organization
• Contract Research Organization

Breakup By Therapeutic Area

• Oncological Diseases
• Metabolic Disorders
• Neurological Disorders
• Respiratory Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Others

Breakup By End User

• Pharmaceutical and Biopharmaceutical Companies
• Medical Devices Companies
• Others

Competitive Landscape

Frequently Asked Questions (FAQs)

1. What is the current size of the Australia Contract Development and Manufacturing Organization (CDMO) Market?
The market was valued at USD 2.03 Billion in 2025.

2. What is the projected CAGR of the Australia Contract Development and Manufacturing Organization (CDMO) Market?
The market is expected to grow at a CAGR of 7.0% during 2026–2035.

3. Which region dominates the Australia Contract Development and Manufacturing Organization (CDMO) Market?
Australia dominates due to strong regulatory systems and advanced pharmaceutical infrastructure.

4. Who are the key players in the Australia Contract Development and Manufacturing Organization (CDMO) Market?
Catalent Inc., Recipharm AB, Boehringer Ingelheim, Patheon Pharma Services, Pfizer Inc., Samsung Biologics Co., Ltd., Lonza Group, WuXi AppTec, FUJIFILM Diosynth Biotechnologies, Nipro Pharma Corporation, B. Braun SE, WuXi Biologics.

5. What are the major growth drivers of the Australia Contract Development and Manufacturing Organization (CDMO) Market?
Biologics expansion, outsourcing demand, government support, and technological advancements are key drivers.

6. What are the key segments of the Australia Contract Development and Manufacturing Organization (CDMO) Market?
Service type, therapeutic area, and end user segments define the market structure.

7. What challenges does the Australia Contract Development and Manufacturing Organization (CDMO) Market face?
High costs, regulatory complexity, and limited large-scale manufacturing capacity are key challenges.

8. What is the forecast value of the Australia Contract Development and Manufacturing Organization (CDMO) Market by 2035?
The market is projected to reach USD 3.99 Billion by 2035.

"

About Us:

Expert Market Research is a global market intelligence and consulting platform by Claight delivering data-driven insights across commodities, chemicals, energy, and industrial markets. We design our research to support businesses, analysts, investors, and procurement teams in understanding price trends, supply-demand dynamics, competitive landscapes, gaining competitive intelligence, benchmarking best practices, and developing long-term market outlooks.

Our robust research methodologies, combined with validated primary and secondary data, ensure accuracy, consistency, and relevance. Our analysis is widely used not only for strategic planning, market-entry assessments, and sourcing decisions, but also for investment evaluation across international markets. Our strong emphasis on transparency, factual reporting, and regular data updates to reflect real-time market conditions always keeps you ahead of the curve.

Media Contact:

Company Name: Claight Corporation
Email: [email protected]
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: C-130 Sector 2 Noida, Uttar Pradesh 201301
Website: https://www.expertmarketresearch.com